QualityDipStocks / Health Care · Medical instruments
Glaukos GKOS
Outside our quality screen, so we don’t track its dips. It’s 2% below its 52-week high.
Outside our quality screen. No fair value estimate for now: the model’s result is too extreme to stand behind.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −2%
- Risk vs market
- Below marketbeta 0.81
2 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 2% below its 52-week high (Oct 29), but the business held up: shares outstanding unchanged, operating margin 0.0 pts, free cash flow 0.0%.
Some numbers held up (shares outstanding unchanged, operating margin 0.0 pts, free cash flow 0.0%), others slipped. The price is 2% below its 52-week high.
The price is 2% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($242.48, Oct 29) the price assumed about 69%/yr free-cash-flow growth; today about 69%. The last 3 years delivered 22%/yr (revenue).
Dashed line: what the last 3 years delivered, 22%/yr (revenue)
| High | Low | Now | |
|---|---|---|---|
| Price | $242.48Oct 29 | $81.79Nov 6 | $238.61 |
| Implied growth | +69% | n/a | +69% |
| P/FCF | 412.0× | — | 405.4× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for GKOS: the model gives 92% below the price; trailing free cash flow is small next to the company's value, so a DCF on it says little. We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, GKOS’s free cash flow would need to grow about 69% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much GKOS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 4.7× the S&P 500’s.
- Beta vs S&P 500
- 0.81
- Volatility
- 60% vs 13% SPY
- Correlation SPY
- 0.17
- Correlation QQQ
- 0.09
How it ranks
Where GKOS stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield0.2% · free cash flow vs market capLowest 17%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+47% · vs the 12 months beforeTop 8%of 1,814
- Operating margin−26% · of sales kept as operating profitLowest 3%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
FCF value $16.92
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
GrowthSales grew 47% to $690M over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 22% a year from FY2022 to FY2025.
Top bearish points 5 of 5
ProfitabilityGross margin narrowed to 55.7% in FY2025 from 76.0% in FY2023 (SEC filings).
Balance sheetOperating income covers interest only -36.6× over the last 12 months.
ProfitabilityLost $170M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −26% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
All fundamentals
FCF yield 0.2% · ROE -23% · Sales +47%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/an/m: free cash flow near zero
- FCF yield
- 0.2%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 21.15×
- Price / book
- 20.36×
- Market cap
- $14.6Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $690M
- Sales growth, 12 months
- +46.9%vs the 12 months before
- Sales growth, 3 yrs
- +21.5%/yrfrom FY2022
- Diluted EPS, 12 months
- −$2.95
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$170M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 64.8%
- Operating margin
- −25.5%
- Net margin
- −24.6%
- FCF margin
- 5.2%
- Return on equity
- −23%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $162M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -36.6×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $36M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +6.6%diluted shares vs a year ago
- Stock-based comp
- $83M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Glaukos’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +58%
- Free cash flow, 12 months$0.0B
- Free-cash-flow yield0.2%
- Gross margin81%
- Operating margin0%
- Return on invested capital0%
- Return on equity−23%
- Sales growth (latest quarter vs year-ago quarter)+58%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $238.61
- 52-wk lowlowest close, 1 year$81.79−65.7%
- PriceMon Nov 2 close$238.61you are here
- 52-wk highhighest close, 1 year$242.48+1.6%
Momentum & 52-week range
RSI 83 · 5 days +33.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
GKOS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Glaukos in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.